Latanoprost intratympanic - Synphora

Drug Profile

Latanoprost intratympanic - Synphora

Alternative Names: JB-004

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synphora
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Meniere's disease; Tinnitus

Highest Development Phases

  • Phase II/III Meniere's disease

Most Recent Events

  • 04 May 2017 Phase-II/III development for Meniere's disease is ongoing in Sweden (Intratympanic) (Synphora website, May 2017)
  • 23 May 2016 Synphora completes a phase II/III trial for Meniere's disease in Sweden (Intratympanic) (EudraCT2013-002261-18; NCT01973114)
  • 24 Feb 2016 Latanoprost intratympanic is available for licensing as of 24 Feb 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top